The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
The high-risk, high-reward nature of the Russell 2000 makes stock selection critical, and we’re here to guide you toward the right ones. That said, here is one Russell 2000 stock that could be the next big thing and two that may face some trouble.
Two Stocks to Sell:
CONMED (CNMD)
Market Cap: $1.29 billion
With over five decades of experience in surgical innovation since its founding in 1970, CONMED (NYSE: CNMD) develops and manufactures medical devices and equipment for surgical procedures, specializing in orthopedic and general surgery products.
Why Is CNMD Not Exciting?
- Constant currency revenue growth has disappointed over the past two years and shows demand was soft
- Modest revenue base of $1.37 billion gives it less fixed cost leverage and fewer distribution channels than larger companies
- Sales are projected to remain flat over the next 12 months as demand decelerates from its two-year trend
CONMED is trading at $42.00 per share, or 9.4x forward P/E. If you’re considering CNMD for your portfolio, see our FREE research report to learn more.
Home Bancshares (HOMB)
Market Cap: $5.90 billion
Founded in Conway, Arkansas in 1998 and growing through strategic acquisitions across the Southeast, Home Bancshares (NYSE: HOMB) operates as the bank holding company for Centennial Bank, providing commercial and retail banking services to businesses and individuals across multiple states.
Why Does HOMB Give Us Pause?
- Sales trends were unexciting over the last two years as its 6.8% annual growth was below the typical banking company
- 9.6% annual net interest income growth over the last five years was slower than its banking peers
- Incremental sales over the last five years were less profitable as its 6.1% annual earnings per share growth lagged its revenue gains
Home Bancshares’s stock price of $29.10 implies a valuation ratio of 1.3x forward P/B. Dive into our free research report to see why there are better opportunities than HOMB.
One Stock to Buy:
Oscar Health (OSCR)
Market Cap: $9.22 billion
Founded in 2012 to simplify the notoriously complex American healthcare system, Oscar Health (NYSE: OSCR) is a technology-focused health insurance company that offers individual and small group health plans through its cloud-native platform.
Why Will OSCR Beat the Market?
- Market share has increased this cycle as its 42.6% annual revenue growth over the last two years was exceptional
- Earnings per share grew by 31.5% annually over the last four years and trumped its peers
- Free cash flow margin jumped by 19.9 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends
At $30.46 per share, Oscar Health trades at 29.3x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
